These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 8428005)
21. [Heparin-induced thrombopenia: significance and difficulties of precise identification of the immunologic mechanism]. Samama MM; Elalamy I; Lecrubier C; Potevin F; Horellou MH; Conard J Bull Acad Natl Med; 1998; 182(7):1517-33; discussion 1534-6. PubMed ID: 9916345 [TBL] [Abstract][Full Text] [Related]
22. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Chong BH; Fawaz I; Chesterman CN; Berndt MC Br J Haematol; 1989 Oct; 73(2):235-40. PubMed ID: 2818941 [TBL] [Abstract][Full Text] [Related]
23. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Chong BH; Burgess J; Ismail F Thromb Haemost; 1993 Apr; 69(4):344-50. PubMed ID: 8497847 [TBL] [Abstract][Full Text] [Related]
24. Cleavage of anti-PF4/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia. Kizlik-Masson C; Deveuve Q; Zhou Y; Vayne C; Thibault G; McKenzie SE; Pouplard C; Loyau S; Gruel Y; Rollin J Blood; 2019 May; 133(22):2427-2435. PubMed ID: 30917957 [TBL] [Abstract][Full Text] [Related]
25. Identifying patients at high risk of heparin-induced thrombocytopenia-associated thrombosis with a platelet activation assay using flow cytometry. Maeda T; Nakagawa K; Murata K; Kanaumi Y; Seguchi S; Kawamura S; Kodama M; Kawai T; Kakutani I; Ohnishi Y; Kokame K; Okazaki H; Miyata S Thromb Haemost; 2017 Jan; 117(1):127-138. PubMed ID: 27734072 [TBL] [Abstract][Full Text] [Related]
26. The unique immunological features of heparin-induced thrombocytopenia. Staibano P; Arnold DM; Bowdish DM; Nazy I Br J Haematol; 2017 Apr; 177(2):198-207. PubMed ID: 28369702 [TBL] [Abstract][Full Text] [Related]
27. Increased risk of thrombosis in FcγRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2. Rollin J; Pouplard C; Sung HC; Leroux D; Saada A; Gouilleux-Gruart V; Thibault G; Gruel Y Blood; 2015 Apr; 125(15):2397-404. PubMed ID: 25680756 [TBL] [Abstract][Full Text] [Related]
28. Heparin-induced thrombocytopenia: a ten-year retrospective. Warkentin TE Annu Rev Med; 1999; 50():129-47. PubMed ID: 10073268 [TBL] [Abstract][Full Text] [Related]
30. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Amiral J; Wolf M; Fischer A; Boyer-Neumann C; Vissac A; Meyer D Br J Haematol; 1996 Mar; 92(4):954-9. PubMed ID: 8616093 [TBL] [Abstract][Full Text] [Related]
31. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. Visentin GP; Ford SE; Scott JP; Aster RH J Clin Invest; 1994 Jan; 93(1):81-8. PubMed ID: 8282825 [TBL] [Abstract][Full Text] [Related]
33. Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome. Slocum MM; Adams JG; Teel R; Spadone DP; Silver D J Vasc Surg; 1996 May; 23(5):839-43. PubMed ID: 8667505 [TBL] [Abstract][Full Text] [Related]
34. Clinical evaluation of acute systemic reaction and detection of IgG antibodies against PF4/heparin complexes in hemodialysis patients. Matsuo T; Wanaka K; Miyasita K; Prechel M; Walenga JM Thromb Res; 2012 Apr; 129(4):474-8. PubMed ID: 22088491 [TBL] [Abstract][Full Text] [Related]
35. A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis. Padmanabhan A; Jones CG; Curtis BR; Bougie DW; Sullivan MJ; Peswani N; McFarland JG; Eastwood D; Wang D; Aster RH Chest; 2016 Sep; 150(3):506-15. PubMed ID: 26905366 [TBL] [Abstract][Full Text] [Related]
36. Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG. Untch B; Ahmad S; Jeske WP; Messmore HL; Hoppensteadt DA; Walenga JM; Lietz H; Fareed J Thromb Res; 2002 Jan; 105(2):117-23. PubMed ID: 11958801 [TBL] [Abstract][Full Text] [Related]
37. Physiological changes in membrane-expressed platelet factor 4: implications in heparin-induced thrombocytopenia. Prechel MM; Jeske WP; Walenga JM Thromb Res; 2010 Apr; 125(4):e143-8. PubMed ID: 19931120 [TBL] [Abstract][Full Text] [Related]
38. How I treat patients with a history of heparin-induced thrombocytopenia. Warkentin TE; Anderson JA Blood; 2016 Jul; 128(3):348-59. PubMed ID: 27114458 [TBL] [Abstract][Full Text] [Related]
39. PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. Reilly MP; Sinha U; André P; Taylor SM; Pak Y; Deguzman FR; Nanda N; Pandey A; Stolla M; Bergmeier W; McKenzie SE Blood; 2011 Feb; 117(7):2241-6. PubMed ID: 21088136 [TBL] [Abstract][Full Text] [Related]
40. Importance of the FcgammaRIIa-Arg/His-131 polymorphism in heparin-induced thrombocytopenia diagnosis. Bachelot-Loza C; Saffroy R; Lasne D; Chatellier G; Aiach M; Rendu F Thromb Haemost; 1998 Mar; 79(3):523-8. PubMed ID: 9531034 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]